Inderjit Kaul - 03 Aug 2026 Form 4 Insider Report for Minerva Neurosciences, Inc. (NERV)

Reporting relationship: Director
Issuer ticker: NERV
Reported as of: 03 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Aug 2026, 18:05:15 UTC
Prior SEC filing: 05 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Frederick Ahlholm, Attorney-in-Fact

Key filing fact

Inderjit Kaul filed Form 4 for Minerva Neurosciences, Inc. (NERV) on 03 Aug 2026.

Key facts

This page summarizes Inderjit Kaul's Form 4 filing for Minerva Neurosciences, Inc. (NERV).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 03 Aug 2026, 18:05.

Change

Previous filing in this sequence was filed on 05 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002095703 Primary reporting owner

Kaul Inderjit

Relationship: Director
Address: C/O MINERVA NEUROSCIENCES, INC., 1500 DISTRICT AVENUE, BURLINGTON
Signature: /s/ Frederick Ahlholm, Attorney-in-Fact
Signature date: 03 Aug 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NERV transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +12,147
Change %
Price: $0.000000^*
Shares after: 12,147
Date: 03 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 12,147
Exercise price: $3.97
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

25% of the option shall vest on November 14, 2026; an additional 45% of the Consultant Option shall vest on the tenth day following the date of the Company's public announcement that it has achieved, on a statistically significant basis, the primary endpoint of its Phase 3 confirmatory trial of roluperidone in schizophrenia at the 12-week timepoint; and the remaining 30% of the Consultant Option shall vest on the tenth day following the date of the Company's public announcement of safety data from the 40-week relapse assessment phase; provided, however, in each case, that the Reporting Person is providing services pursuant to that certain consulting agreement dated November 14, 2025 on each such vesting date.